α1-Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms

[1]  I Rovira,et al.  Nitric oxide , 2021, Reactions Weekly.

[2]  H. Lepor,et al.  The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study. , 2000, The Journal of urology.

[3]  C. Vancheri,et al.  Mitogenic effect of nerve growth factor (NGF) in LNCaP prostate adenocarcinoma cells: role of the high- and low-affinity NGF receptors. , 2000, Molecular endocrinology.

[4]  S. Seo,et al.  Effects of partial bladder outlet obstruction and its relief on types I and III collagen and detrusor contractility in the rat. , 2000, Neurourology and urodynamics.

[5]  Bradford D. Winters,et al.  Subtype Specific Regulation of Human Vascular α1-Adrenergic Receptors by Vessel Bed and Age , 1999 .

[6]  R. Bruskewitz.  Management of Symptomatic BPH in the US: Who Is Treated and How? , 1999, European Urology.

[7]  H. Klingler,et al.  Regulation of prostatic stromal cell growth and function by transforming growth factor beta (TGFβ) , 1999, The Prostate.

[8]  R. Kim,et al.  Alpha1A-adrenergic receptor polymorphism: association with ethnicity but not essential hypertension. , 1999, Pharmacogenetics.

[9]  D. Djakiew,et al.  Characterization of nerve growth factor precursor protein expression by human prostate stromal cells: A role in selective neurotrophin stimulation of prostate epithelial cell growth , 1999, The Prostate.

[10]  Ukai,et al.  Contractile responses to α1‐adrenoceptor agonists in isolated human male and female urethra , 1999, BJU international.

[11]  R. Villalobos-Molina,et al.  Vascular alpha 1D-adrenoceptors: are they related to hypertension? , 1999, Archives of medical research.

[12]  D. Garvey,et al.  Design and evaluation of nitrosylated alpha-adrenergic receptor antagonists as potential agents for the treatment of impotence. , 1999, The Journal of pharmacology and experimental therapeutics.

[13]  C. Sáez,et al.  Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride , 1999, The Prostate.

[14]  D.J. Martin.  Preclinical Pharmacology of α1-Adrenoceptor Antagonists , 1999, European Urology.

[15]  J. Hieble,et al.  Effects of alpha1-adrenoceptor antagonists on agonist and tilt-induced changes in blood pressure: relationships to uroselectivity. , 1999, European journal of pharmacology.

[16]  W. Steers,et al.  Persistently increased voiding frequency despite relief of bladder outlet obstruction. , 1999, The Journal of urology.

[17]  W. Steers,et al.  Altered NGF regulation may link a genetic predisposition for hypertension with hyperactive voiding. , 1999, The Journal of urology.

[18]  H. Lepor,et al.  Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. , 1999, The Journal of urology.

[19]  W. Steers,et al.  The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males , 1999, Experimental physiology.

[20]  J. Gosling,et al.  The distribution of noradrenergic nerves in the human lower urinary tract. A review. , 1986, European urology.

[21]  E. Rimm,et al.  Physical activity and benign prostatic hyperplasia. , 1998, Archives of internal medicine.

[22]  A. Tewari,et al.  A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. , 1998, The Journal of urology.

[23]  K. Kimura,et al.  The alpha1L-adrenoceptor subtype in the lower urinary tract: a comparison of human urethra and prostate. , 1998, British journal of urology.

[24]  W. Steers,et al.  Altered regulation of bladder nerve growth factor and neurally mediated hyperactive voiding. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[25]  W. Steers,et al.  Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. , 1998, The American journal of physiology.

[26]  C. D. Richardson,et al.  Alpha1-adrenergic receptor subtypes in human detrusor. , 1998, The Journal of urology.

[27]  W. Steers,et al.  The incidence of a positive ice water test in bladder outlet obstructed patients: evidence for bladder neural plasticity. , 1998, The Journal of urology.

[28]  H. Lepor.  Long-Term Evaluation of Tamsulosin in Benign Prostatic Hyperplasia: Placebo-Controlled, Double-Blind Extension of Phase III Trial , 1998 .

[29]  H. Lepor.  Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. , 1998, Urology.

[30]  A. Borkowski,et al.  Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. , 1998, The Journal of urology.

[31]  H. Lepor,et al.  Endothelin‐1 production and agonist activities in cultured prostate‐derived cells: Implications for regulation of endothelin bioactivity and bioavailability in prostatic hyperplasia , 1998, The Prostate.

[32]  K. Andersson.  The Concept of Uroselectivity , 1998, European Urology.

[33]  R. Kirby,et al.  Morning vs evening dosing with doxazosin in benign prostatic hyperplasia: efficacy and safety , 1998, Prostate Cancer and Prostatic Diseases.

[34]  P. Casale,et al.  Relationship among symptom score, prostate volume, and urinary flow rates in 543 patients with and without benign prostatic hyperplasia , 1998, The Prostate.

[35]  M. Levenstein,et al.  Effects of doxazosin in patients with mild, intermediate, and severe benign prostatic hyperplasia. , 1998, Clinical therapeutics.

[36]  P. Dasgupta,et al.  Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term followup. , 1997, The Journal of urology.

[37]  R. Sakakibara,et al.  The nature of detrusor bladder neck dyssynergia in non-neurogenic bladder dysfunction. , 1997, Journal of the autonomic nervous system.

[38]  W. Witjes,et al.  Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. , 1997, British journal of urology.

[39]  E. Guillot,et al.  Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. , 1997, The Journal of pharmacology and experimental therapeutics.

[40]  K. Andersson,et al.  Heme oxygenase and NO-synthase in the human prostate--relation to adrenergic, cholinergic and peptide-containing nerves. , 1997, Journal of the autonomic nervous system.

[41]  T. Tanaka,et al.  Identification of alpha1-adrenoceptor subtypes in the human prostatic urethra , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[42]  S. Roth,et al.  Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. , 1997, European urology.

[43]  J. Hieble,et al.  Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I. , 1997, The Journal of pharmacology and experimental therapeutics.

[44]  G. Tsujimoto,et al.  Quantification and distribution of α1‐adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non‐hypertrophied tissue , 1996, British journal of pharmacology.

[45]  C. Roehrborn,et al.  Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. , 1996, Urology.

[46]  A. Naylor,et al.  Evaluation of the pharmacological selectivity profile of α1 adrenoceptor antagonists at prostatic α1 adrenoceptors: binding, functional and in vivo studies , 1996 .

[47]  L K Lloyd,et al.  The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. , 1996, Urology.

[48]  S. Harrap,et al.  Nerve growth factor gene and hypertension in spontaneously hypertensive rats , 1996, Journal of hypertension.

[49]  J. Cheng,et al.  The norepinephrine tissue concentration and neuropeptide Y immunoreactivity in genitourinary organs of the spontaneously hypertensive rat. , 1996, Journal of the autonomic nervous system.

[50]  彰 波田野.  Pharmacological evidence of distinct α[1]-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery , 1996 .

[51]  P. Abrams,et al.  Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. , 1996, European urology.

[52]  M. Wyllie,et al.  A comparison of the effects of doxazosin and terazosin on the spontaneous sympathetic drive to the bladder and related organs in anaesthetized cats. , 1995, European journal of pharmacology.

[53]  U. Schambra,et al.  α1-Adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding α1-adrenergic receptor subtypes at four distinct levels , 1995 .

[54]  H. Vargas,et al.  Vascular alpha-1 adrenergic receptor subtypes in the regulation of arterial pressure. , 1995, Life sciences.

[55]  M. Fall,et al.  Clinical and urodynamic effects of intravesical capsaicin treatment in patients with chronic traumatic spinal detrusor hyperreflexia. , 1995, The Journal of urology.

[56]  M Gaffney,et al.  Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. , 1995, The Journal of urology.

[57]  M. Gaffney,et al.  Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. , 1995, The Journal of urology.

[58]  R. Lefkowitz,et al.  International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. , 1995, Pharmacological reviews.

[59]  H. Lepor,et al.  Pathophysiology of clinical benign prostatic hyperplasia. , 1995, The Urologic clinics of North America.

[60]  W. C. Groat,et al.  Prejunctional facilitatory α1‐adrenoceptors in the rat urinary bladder , 1995 .

[61]  K. Thor,et al.  Inhibition of central sympathetic and somatic outflow to the lower urinary tract of the cat by the alpha 1 adrenergic receptor antagonist prazosin. , 1995, The Journal of urology.

[62]  H. Lepor,et al.  Characterization and localization of nitric oxide synthase in the human prostate. , 1995, Urology.

[63]  H. Lepor,et al.  Effects of nitric oxide on human and canine prostates. , 1995, Urology.

[64]  H. Lepor.  Benign prostatic hyperplasia. , 1995, The Journal of urology.

[65]  P. Abrams,et al.  Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. , 1995, British journal of urology.

[66]  A. Goetz,et al.  Characterization of alpha-1 adrenoceptor subtypes in human and canine prostate membranes. , 1994, The Journal of pharmacology and experimental therapeutics.

[67]  I. Muramatsu,et al.  Heterogeneity of α1‐adrenoceptor subtypes involved in adrenergic contractions of dog blood vessels , 1994, British journal of pharmacology.

[68]  M. Wyllie,et al.  Effect of alpha 1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog. , 1994, Urology.

[69]  S. Yamada,et al.  COMPARATIVE STUDY ON α1‐ADRENOCEPTOR ANTAGONIST BINDING IN HUMAN PROSTATE AND AORTA , 1994 .

[70]  S. Lindström,et al.  Positive bladder cooling test in neurologically normal young children. , 1994, The Journal of urology.

[71]  K. Chihara,et al.  Expression of basic fibroblast growth factor (FGF-2) messenger ribonucleic acid is regulated by testosterone in the rat anterior pituitary. , 1994, Growth factors.

[72]  W. Steers,et al.  Calcium channel antagonists prevent urinary bladder growth and neuroplasticity following mechanical stress. , 1994, The American journal of physiology.

[73]  R C Bruskewitz,et al.  Benign Prostatic Hyperplasia , 1994, Springer Berlin Heidelberg.

[74]  M. Brawer,et al.  Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. , 1993, Archives of family medicine.

[75]  M. Caron,et al.  Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. , 1993, The Journal of urology.

[76]  A T Cockett,et al.  Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. , 1993, The Journal of urology.

[77]  H. Lepor,et al.  Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. , 1993, The Journal of urology.

[78]  E. Rudelle,et al.  [Treatment of benign prostatic hypertrophy]. , 1993, Soins. Chirurgie.

[79]  J. Williams,et al.  Experimental model of bladder outflow tract obstruction in the guinea-pig. , 1993, British journal of urology.

[80]  H. Lepor,et al.  Quantitative morphometry of the adult human bladder. , 1992, The Journal of urology.

[81]  S. Furukawa,et al.  Increased nerve growth factor levels in spontaneously hypertensive rats , 1992, Journal of hypertension.

[82]  W. Steers,et al.  Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. , 1991, The Journal of clinical investigation.

[83]  H. Bensadoun,et al.  Alfuzosin for treatment of benign prostatic hypertrophy , 1991, The Lancet.

[84]  G. Jennings,et al.  Biochemical evidence of sympathetic hyperactivity in human hypertension. , 1991, Hypertension.

[85]  T. Tammela,et al.  The bladder cooling test for urodynamic assessment: analysis of 400 examinations. , 1991, British journal of urology.

[86]  W. D. de Groat,et al.  Sympathetic modulation of cholinergic transmission in cat vesical ganglia is mediated by alpha 1- and alpha 2-adrenoceptors. , 1990, The American journal of physiology.

[87]  G. Burnstock,et al.  Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. , 1989, British journal of urology.

[88]  A. Mundy,et al.  The density of cholinergic and alpha and beta adrenergic receptors in the normal and hyper-reflexic human detrusor. , 1989, British journal of urology.

[89]  M. Caine.  The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. , 1986, The Journal of urology.

[90]  K. Andersson,et al.  Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate. , 1985, The Journal of urology.

[91]  J. Hieble,et al.  In vitro characterization of the alpha-adrenoceptors in human prostate. , 1985, European journal of pharmacology.

[92]  L. Cassis,et al.  Altered catecholamine contents in vascular and nonvascular tissues in genetically hypertensive rats. , 1985, Blood vessels.

[93]  H. Lepor,et al.  Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia. , 1984, The Journal of urology.

[94]  C. Stoney,et al.  Is the hypertensive rat really hyperreactive? , 1984, Hypertension.

[95]  S. Lundin,et al.  Renal sympathetic activity in spontaneously hypertensive rats and normotensive controls, as studied by three different methods. , 1984, Acta physiologica Scandinavica.

[96]  K. A. Blinn,et al.  Spinal reflex activity from the vesical mucosa in paraplegic patients. , 1957, A.M.A. archives of neurology and psychiatry.